Publicaciones científicas

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

Weigelin B(1), Bolaños E(2), Teijeira A(2), Martinez-Forero I(2), Labiano S(2), Azpilikueta A(2), Morales-Kastresana A(2), Quetglas JI(2), Wagena E(1), Sánchez-Paulete AR(2), Chen L(3), Friedl P(1), Melero I(4).

(1) Department of Cell Biology, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands;
(2) Centro de Investigación Médica Aplicada (CIMA) and Clinica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain;
(3) Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511;
(4) Centro de Investigación Médica Aplicada (CIMA) and Clinica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.

Revista: Proceedings of the National Academy of Sciences of the United States of America

Fecha: 16/06/2015

Oncología Médica

Resumen

Cancer immunotherapy is undergoing significant progress due to recent clinical successes by refined adoptive T-cell transfer and immunostimulatory monoclonal Ab (mAbs). B16F10-derived OVA-expressing mouse melanomas resist curative immunotherapy with either adoptive transfer of activated anti-OVA OT1 CTLs or agonist anti-CD137 (4-1BB) mAb.

However, when acting in synergistic combination, these treatments consistently achieve tumor eradication. Tumor-infiltrating lymphocytes that accomplish tumor rejection exhibit enhanced effector functions in both transferred OT-1 and endogenous cytotoxic T lymphocytes (CTLs). This is consistent with higher levels of expression of eomesodermin in transferred and endogenous CTLs and with intravital live-cell two-photon microscopy evidence for more efficacious CTL-mediated tumor cell killing.

Anti-CD137 mAb treatment resulted in prolonged intratumor persistence of the OT1 CTL-effector cells and improved function with focused and confined interaction kinetics of OT-1 CTL with target cells and increased apoptosis induction lasting up to six days postadoptive transfer. The synergy of adoptive T-cell therapy and agonist anti-CD137 mAb thus results from in vivo enhancement and sustainment of effector functions.

CITA DEL ARTÍCULO Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112.

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra